Barings LLC Boosts Stock Position in Eli Lilly and Company $LLY

Barings LLC modestly increased its Eli Lilly stake to 1,246 shares (up 4.6%) worth $971k as a range of other institutional investors made small buys and sells, leaving institutional ownership at 82.5%. Analysts have trended more bullish recently—BMO lifted its target to $1,100, Scotiabank initiated at $1,165 and MarketBeat shows a consensus “Moderate Buy” target of $1,027.95—while the stock trades around $1,058 with a ~$1.0 trillion market cap and a rich PE of ~69. The company reported a solid quarter (EPS $7.02 vs $6.42 est; revenue $17.6bn vs $16.09bn, +53.9% y/y), set FY25 EPS guidance of $23.00–23.70, and pays a modest $1.50 quarterly dividend (annual yield ~0.6%), suggesting strong underlying growth that supports higher analyst targets but leaves valuation and margin of safety as key considerations for investors.

Analysis

Barings LLC increased its Eli Lilly stake by 4.6% to 1,246 shares valued at $971,000 in Q2, while a number of other institutional and smaller investors made marginal buys and sells, leaving institutional ownership at 82.53%. These position changes are small relative to Eli Lilly’s $1.00 trillion market cap, indicating continued institutional conviction but limited incremental flows from the filings cited.

The company reported a meaningful earnings beat on October 30: $7.02 EPS versus $6.42 consensus and revenue of $17.60 billion versus $16.09 billion, a 53.9% year‑over‑year increase; net margin was 25.91% and ROE 92.72%. Management set FY2025 EPS guidance of $23.00–$23.70, roughly in line with the analyst consensus of 23.48, supporting the revenue and earnings trajectory reflected in the print.

Market pricing reflects that growth: the stock opened at $1,058.05, near its 12‑month high, with a PE of 69.15 and PEG of 1.21; the 50‑ and 200‑day moving averages ($855.89 and $787.74) show an elevated trend. Analysts have trended bullish (BMO $1,100, Scotiabank $1,165; consensus target $1,027.95) while the dividend is modest ($1.50 qtr., 0.6% yield, 29.35% payout); primary risks are valuation compression and execution versus the FY25 range.

Key Decisions for Investors

• Consider maintaining or modestly adding to positions given the strong quarter and FY25 guidance, but size new buys conservatively because the stock trades at a stretched PE (~69) and near its 12‑month high
• Monitor execution against the $23.00–$23.70 FY25 EPS range and upcoming quarterly releases as the primary catalysts that would justify higher analyst targets
• If the share price moves above the higher analyst targets (roughly $1,100–$1,165) or margin expansion stalls, consider partial profit‑taking or hedging while watching leverage (debt‑to‑equity 1.86) and the 29% payout ratio for dividend sustainability